Objective: Guidelines on the management of thyroid dysfunction during pregnancy have recently been updated and, for the diagnosis of subclinical hypothyroidism (SCH), a thyroid-stimulating hormone (TSH) upper reference limit (cut-off) of 4.0 mIU/L has been proposed when no institutional values are available. It is also suggested that serum TSH and thyroid autoimmunity (TAI) may be different according to the ethnic background of the women. We therefore determined the prevalence of TAI and SCH
| INTRODUCTION
Differences in the prevalence of thyroid autoimmunity (TAI) and subclinical hypothyroidism (SCH) have been documented in women with different ethnic backgrounds in the general population in the USA. 1, 2 In pregnant women, data are limited to two studies in the USA and two in the Netherlands. [3] [4] [5] [6] In the first study performed in the USA by Walker et al., 3 there was no difference in the prevalence of TAI between women with African American and Caucasian backgrounds and in the second study by La'ulu et al. 4 ; the prevalence of TAI was lower in African American women, which may be due to their younger age. In the first study performed in the Netherlands by Benhadi et al., 5 no difference was observed in the prevalence of TAI between pregnant women of Turkish, Moroccan, Surinamese and Dutch origin, and in the other Dutch study, pregnant women of Turkish origin had a higher prevalence of TAI. 6 Differences in thyroid function were sometimes investigated independently from that of TAI. [3] [4] [5] [6] [7] [8] In two studies performed in the USA, African
American women had significantly lower TSH levels as compared with Caucasian women. 3, 7 However, in the study by Pearce et al., 8 no differences in serum TSH levels were observed. In the two studies performed in the Netherlands, higher mean serum TSH levels were present in the group of Dutch women as compared to those in women with other backgrounds, but in the more recent study by Korevaar et al., 6 Turkish and Dutch women had comparable serum TSH levels. 5 Concerning the diagnosis of SCH during pregnancy, in the revised American Thyroid Association (ATA) and Endocrine Society (ES) guidelines, it is proposed to use institutional trimesterspecific TSH upper reference limit values and, when not available, a first trimester cut-off value for the upper limit of ~4.0 mIU/L (ATA) and 2.5 mIU/L (ES 2012). 9, 10 Some authors have also proposed optimizing trimester-specific TSH reference ranges by adding ethnic specificity. 6, 8 In the paper by Korevaar et al., 6 the authors showed that when ethnic trimester-specific reference ranges were used, the diagnosis of thyroid dysfunction would change in 13% of women compared with when population-based cut-off levels were used.
Altogether, the aims of our study were 1/to investigate and compare the prevalence of TAI and TSH/SCH during the first trimester of pregnancy in our study group of women with sub-Saharan (Congolese), North African (Moroccan) and Caucasian backgrounds, and 2/to determine institutional and ethnicity-specific TSH reference ranges and to compare the prevalence of SCH, when determined according to these cut-offs and the 2.5 mIU/L and 4.0 mIU/L cut-off levels.
| PATIENTS AND METHODS

| Overall study design
The obstetric clinic of the CHU St-Pierre is a downtown, public university (tertiary referral) maternity centre in Brussels (Belgium), with about 3200 deliveries per year.
We report here on data of a cross-sectional analysis of pregnant women (period 2013-2014) that was nested within the ongoing pro- Caucasian background (CaBg) were included in the study; they represent the majority of pregnant women consulting at our centre.
In all medical files, ethnicity is always recorded, based on the systematically raised question "what was your nationality at birth?".
This means that pregnant women identified as from sub-Saharan and North African origin are correctly identified. Finally and after exclusion of women with other backgrounds (mainly Turkish, Hispanic and Middle East Asian; n=221), 1683 were included for comparison of thyroid parameters and baseline characteristics. In Figure 1 , we illustrate the inclusion/exclusion criteria with a flow chart.
The first antenatal consultation (median [IQR] 11 [9] [10] [11] [12] [13] [14] weeks) was systematically completed with a biological analysis including TSH, free T4 (FT4) and TPO-ab measurement, while parity and smoking habit were noted at follow-up consultations. In the three groups of women, parameters were expressed as continuous values for TSH, FT4, BMI, age and parity and as categorical data for TAI (TPO-ab >60 IU/L), obesity (BMI ≥30 kg/m²), older age (≥30 years), high parity (>3 children), tobacco use (yes/no) and SCH. For determination of the prevalence of SCH, different first trimester upper limit TSH cut-off levels were used: ethnicity-specific, institutional, the proposal of the ES when no institutional levels are available (2.5 mIU/L) and finally the upper limit for TSH for nonpregnant women provided by the commercial assay (≥4.0 mIU/L), which is also the proposal of the ATA in their recently published guidelines, when no institutional cut-off level is available. 9, 10 For the calculation of institutional reference ranges, women with twin pregnancies (n=38), assisted pregnancies (n=42) and TAI (n=131) were excluded; furthermore, women taking LT4 and/or antithyroid drugs were excluded for the determination of the prevalence of TAI/SCH (cf also Figure 1 The use of ethnicity-specific TSH cut-offs in early pregnancy was not more specific for the diagnosis of SCH as compared to the use of the institutional cut-off.
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ethnic background, hypothyroidism, pregnancy, thyroid, TSH reference ranges higher than the upper limit and lower than the lower limit were removed from the data. We only had to exclude outliers in the upper levels (n=13). For the ethnicity-specific reference ranges, only data from women of the concerned ethnic group were used.
The study was approved by the institutional review board (AK/15-11-114/4568).
| Serum assays
All assays were performed in the hormone laboratory of our institu- The total imprecision CVs were 6.9%, 4.2% and 7.6% for TSH, FT4 and TPO-ab, respectively.
| Statistical analysis
Data were stored in a Microsoft Excel database, and statistical analyses were performed using Stata 11. All statistical tests were considered significant whenever P<.05.
| RESULTS
Forty-two women (2.5%) were pregnant after IVF treatment (six in the In the whole study group, two women had overt hypothyroidism:
one (0.4%) with serum TSH levels >2.5 <4.0 mIU/L (in the NaBg group) and one (1.8%) with serum TSH levels >4.0 mIU/L (in the CaBg group).
Three women had overt hyperthyroidism (0.18%), one in each study group (P=ns among groups). P<.001, respectively). The given P values are after correction for twin and assisted pregnancies.
TPO-ab levels were comparable between all groups (data not shown). Table 3 .
In the upper part of the table, it is shown that the mean serum TSH levels tended to be higher (but not significantly) in the group of all women (without twin and assisted pregnancies, but with TAI) as compared with women without TAI. After the exclusion of outliers, women with twin or assisted pregnancies and TAI, the reference values from our The given P value is multiplied by 4 for multiple comparisons. * Give the significance between the different study groups.
upper limits (3.96 mIU/L) in the CaBg group were higher than in the other groups; cf Table 3 for details. Table 4 .
The prevalence of SCH defined with the 2.5 mIU/L cut-off was much higher as compared with that when SCH was defined with the other cut-offs. This was true for all women and also within the different background groups. No difference in the prevalence of SCH was observed between the different ethnic groups, when the 2.5 mIU/L cut-off was used.
When the institutional or commercial cut-off was used, the prevalence of SCH was always higher in the CaBg group as compared with the NaBg group (7.1% vs 3.3% and 5.4% vs 2.1%; P=.013 and .008, respectively). No differences were present when ethnicity-specific cut-offs were used.
The prevalence of SCH calculated with the institutional cut-off was comparable with that obtained with ethnicity-specific cut-off values, in the SaBg group (4.2% vs 4.8%), in the NaBg group (3.3% vs 3.9%) and in the CaBg group (7.1% vs 6.0%).
| DISCUSSION
One of the main observations in our study was the low prevalence of TAI in pregnant women with a sub-Saharan African background. In the study by La'ulu et al. 4 in the USA, the prevalence of TAI was also lower in African American women as compared with that in Caucasian American women, but in another study in the USA, no difference was present. 3 Studies performed in the USA cannot however be compared to those performed in Belgium for a number of reasons, such as different population backgrounds, iodine status and prevalence of obesity. The reasons for our observation thus remain speculative.
Smoking and smoking cessation have been associated with a lower and a higher prevalence of thyroid antibodies (Hashimoto's disease), respectively. [12] [13] [14] In our study cohort, women with a Caucasian background smoked more than women with other backgrounds, but they had the highest prevalence of TAI. We did not record the number of women who stopped smoking before pregnancy, what might have been important since it has been associated with the appearance of TAI. 12 The opposite was true in the SaBg group, in which the prevalence of TAI and that of smokers were the lowest. Older age is a variable associated with an increased prevalence of TAI. 2, 15 In the study of La'ulu and Roberts, 4 the lower age of women in the African American study group as compared with the Caucasian group was the author's explanation for the lower prevalence of TAI. In our study however, the mean ages and the prevalence of older women were the same between SaBg and CaBg groups. Obesity has also been associated with an increased prevalence of TAI, a mechanism that is probably mediated by leptin. 16, 17 However, the prevalence of obesity was highest in women of the SaBg group, and therefore, this does not seem to explain the lower prevalence of TAI. More recently, parity has been proposed as a variable contribution in the development of TAI, through the so-called microchimerism. [18] [19] [20] In most studies, however, no association between parity and TAI was obtained 20 and our study results are in line with those results as the SaBg group had lowest prevalence of TAI and the highest parity rate.
Although we did not measure vitamin D and iodine levels in our patients, these two factors merit discussion in relation to TAI. Data on the association between vitamin D deficiency and TAI remain controversial (for review, cf 21). Severe vitamin D deficiency has been described in pregnant women, but probably does not explain the low prevalence of TAI in women of the SaBg group as in a survey performed in the Brussels area, low vitamin D levels were equally distributed among women with different backgrounds. 22, 23 Data on the prevalence of TAI in pregnant women after iodine fortification programmes (f.i. e.g. in Denmark) taught us that its prevalence increased 10 years later. 24 In
Belgium however, attempts to increase the daily iodine intake have not been implemented by the authorities and are still voluntary. In a study performed a few years ago in Brussels (including in our centre), it was shown that (low) urinary iodine levels were not associated with ethnicity and that the median [IQR] urinary iodine was 117 [70-189] ug/L. 25, 26 Besides stress and other environmental factors, genetic predisposition is a key factor in the pathophysiology of autoimmune thyroid disease and might be different in women with different backgrounds.
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T A B L E 4 Prevalence of SCH, defined according to different cutoff upper limit values In all women and according to the ethnic backgrounds The given P value is multiplied by 4 for multiple comparisons.
When considering TSH levels as a continuous variable, these were highest in the CaBg group; results are in line with three studies performed in the USA. 3, 4, 8 Obesity is known to be associated with higher serum TSH levels, but women in the CaBg group had the lowest prevalence of obesity. According to Walker et al., 3 the lower TSH levels in African American women were due to higher hCG levels in African
American women as compared to those in Caucasian women. Also in the study by Korevaar et al., 28 Caucasian women had lower hCG levels as compared with those in Moroccan women; but no women of subSaharan origin were included. Although we did not measure hCG levels in our study, the median gestational age at the first antenatal visit was higher in the SaBg group than in the CaBg group, and because hCG levels are already slightly lower at week 11, compared to week 10, they cannot explain the lower serum TSH levels in the SaBg group.
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Thyroid-pituitary set-point differences may also play a role, as it was shown in blood spots performed for birth screening that mean TSH levels differed according to the ethnicity of the babies.
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The presence of TAI and increased serum TSH levels has been associated with impaired pregnancy outcomes such as (recurrent) first trimester miscarriage, preterm delivery, low birthweight and postpartum thyroiditis. 10, [30] [31] [32] One of the difficulties in interpreting the results of these studies is the heterogeneity in the definition of SCH as different cut-offs for the TSH upper limit were applied. The guidelines from the ES (2012) and the recently updated ATA guidelines on the management of thyroid disorders during pregnancy propose to determine institutional/population-based first trimester-and assay-specific reference ranges. 9, 10 When not available, the ES guidelines propose an upper TSH limit of 2.5 mIU/L during the first trimester, a proposal based on six studies available at that time. 10 The recent ATA guidelines have increased that limit to ~4.0 mIU/L, based on a larger number of patients (~60 000) from 15 studies. 9 Our results are in line with the ATA recommendations, as we obtained an upper limit of 3.7 mIU/L as our institutional cut-off. The increase in the upper limit of TSH will imply that many women with a previous diagnosis of SCH will now be considered as euthyroid and thus be spared LT4 treatment, repetitive blood sample controls, medical visits, etc. The prevalence of SCH in our study was very high when determined with the 2.5 mIU/L cut-off (16.7%) and that decreased by more than >70% (to 4.5%) when it was defined according to the institutional cut-off value. The fact that some recent studies found no association between thyroid dysfunction and altered pregnancy outcomes can also be explained by the use of the 2.5 mIU/L cut-off value for the diagnosis of SCH. 33 In order to increase the specificity of SCH diagnosis in pregnant women, Korevaar et al. proposed to add ethnic background as a variable to the populationand trimester-specific reference ranges. In their study, it was shown that this could have changed the diagnosis of thyroid dysfunction during pregnancy in 13% of women as compared with that when only population-specific reference ranges were used. 6 We did not observe significant differences in the prevalence of SCH when it was determined with institutional or ethnicity-specific cut-offs.
Some weaknesses of our study are as follows: the fact that we did not measure Tg-ab. The importance of Tg-ab in some patients is also noticed in the recent ATA guidelines, but at the same time, they mention that in the vast majority of studies, TAI was only investigated in relation to pregnancy (outcomes) by the presence of TPO-ab. 30, 31, 34, 35 For this reason, the committee recommends only to measure TPO-ab when testing for the presence of TAI. 9 Concerning the determination of ethnicity, some heterogeneity could have been present in the CaBg group, as women from the third immigration generation might have been classified as Caucasian. And finally, would it have been useful if we had measured hCG levels, to be added as a confounder in the analyses. 
